Copyright
©The Author(s) 2016.
World J Gastroenterol. Dec 14, 2016; 22(46): 10232-10241
Published online Dec 14, 2016. doi: 10.3748/wjg.v22.i46.10232
Published online Dec 14, 2016. doi: 10.3748/wjg.v22.i46.10232
Variable | Number of patients | |
Sex | Male | 46 |
Female | 19 | |
Age (yr; mean, range) | 58.8; 33-76 | |
Gastrectomy | Distal | 29 |
Total | 32 | |
None | 4 | |
Surgical curability | R0 | 57 |
R1 | 0 | |
R2 | 8 | |
Clinical course | Survival without relapse | 47 |
Survival after relapse | 2 | |
Survival after non-curative surgery | 1 | |
Decease | 15 | |
Recurrence site (including overlap) | None | 47 |
Remnant stomach | 1 | |
Hematogenous | 5 | |
Lymphatic | 4 | |
Peritoneal dissemination | 5 | |
Non-curative surgery | 8 | |
Postoperative chemotherapy | None | 37 |
Adjuvant chemotherapy | 11 | |
Adjuvant and therapeutic chemotherapy | 9 | |
Therapeutic chemotherapy after non-curative surgery | 8 | |
TNM stage | I | 40 |
II | 6 | |
III | 10 | |
IV | 9 | |
Depth of tumour invasion | T1 | 36 |
T2 | 8 | |
T3 | 9 | |
T4 | 12 | |
Lymph node metastasis | N0 | 39 |
N1 | 5 | |
N2 | 6 | |
N3 | 15 | |
Distant metastasis | M0 | 56 |
M1 | 9 | |
Main histological type | Differentiated | 25 |
Undifferentiated | 40 | |
Lymphatic invasion | L0 | 35 |
L1 | 26 | |
LX | 4 | |
Venous invasion | V0 | 35 |
V1-2 | 26 | |
VX | 4 |
Variable | Univariate analysis | Multivariate analysis | ||||
Hazard ratio | 95%CI | P value | Hazard ratio | 95%CI | P value | |
Number of high telomerase activity cells | ||||||
≤ 5 | 1.0 | 1.0 | ||||
> 5 | 2.069 | 0.693-5.744 | 0.183 | 0.900 | 0.294-2.591 | 0.847 |
fStage | ||||||
fStage I | 1.0 | 1.0 | ||||
fStage II | 7.097 | 0.281-179.3 | 0.196 | 7.106 | 0.281-179.6 | 0.182 |
fStage III | 25.18 | 4.053-482.6 | 0.0003b | 26.17 | 4.017-510.6 | 0.0004b |
fStage IV | 83.57 | 14.86-1567 | < 0.0001b | 85.76 | 14.91-1623 | < 0.0001b |
Variable | Univariate analysis | Multivariate analysis | ||||
Hazard ratio | 95%CI | P value | Hazard ratio | 95%CI | P value | |
Number of high telomerase activity cells | ||||||
≤ 5 | 1.0 | 1.0 | ||||
> 5 | 3.566 | 0.988-12.88 | 0.052 | 1.971 | 0.471-8.861 | 0.350 |
fStage | ||||||
fStage I | 1.0 | 1.0 | ||||
fStage II | 3.635 | 0.169-37.96 | 0.337 | 3.576 | 0.166-37.35 | 0.343 |
fStage III | 17.78 | 4.065-121.8 | 0.0001b | 13.75 | 2.806-100.7 | 0.001b |
fStage IV | 239.6 | 7.943-7785 | 0.005b | 289.4 | 9.331-9733 | 0.004b |
- Citation: Ito H, Sato J, Tsujino Y, Yamaguchi N, Kimura S, Gohda K, Murakami K, Onimaru M, Ohmori T, Ishikawa F, Inoue H. Long-term prognostic impact of circulating tumour cells in gastric cancer patients. World J Gastroenterol 2016; 22(46): 10232-10241
- URL: https://www.wjgnet.com/1007-9327/full/v22/i46/10232.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i46.10232